NASDAQ:ALDX Aldeyra Therapeutics Q3 2026 Earnings Date & Estimates $0.92 -0.03 (-3.31%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.91 0.00 (-0.47%) As of 10/9/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aldeyra Therapeutics is expected to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for November 5, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeBefore Market OpensConference Call DateNovember 5, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Aldeyra Therapeutics in Q3 2026Aldeyra Therapeutics is expected to post earnings of -$0.11 per share on revenue of $2.50 million. In the same quarter a year earlier Aldeyra Therapeutics reported -$0.13 per share. Aldeyra Therapeutics last reported on August 6, 2026, posting -$0.09 per share and missing the -$0.0875 consensus estimate. Aldeyra Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.11Expected Revenue$2.50 millionPrior-Year EPS-$0.13Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.09 (Missed by -$0.0025)EPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Aldeyra Therapeutics Q3 2026 Earnings FAQ When does Aldeyra Therapeutics report Q3 2026 earnings? Aldeyra Therapeutics (NASDAQ:ALDX) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Aldeyra Therapeutics' Q3 2026 earnings call? Aldeyra Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Aldeyra Therapeutics? Analysts expect Aldeyra Therapeutics to post earnings of -$0.11 per share for Q3 2026. How much revenue is Aldeyra Therapeutics expected to report? The consensus revenue estimate for Aldeyra Therapeutics is $2.50 million for Q3 2026. Aldeyra Therapeutics Earnings HeadlinesAldeyra plans FDA dispute request for reproxalapOctober 2, 2026 | americanbankingnews.comAldeyra Therapeutics (NASDAQ:ALDX) Stock Rating Reaffirmed as Neutral by HC WainwrightOctober 2, 2026 | americanbankingnews.comWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent.October 10 at 1:00 AM | Stansberry Research (Ad)Aldeyra Therapeutics (NASDAQ:ALDX) Stock Rating Reaffirmed as Buy by BTIG ResearchOctober 1, 2026 | americanbankingnews.comAldeyra Therapeutics, Inc. Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye DiseaseSeptember 29, 2026 | marketscreener.comMAldeyra Therapeutics plans formal FDA dispute resolution request for Reproxalap after third complete response letterSeptember 29, 2026 | msn.comSee More Aldeyra Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aldeyra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aldeyra Therapeutics and other key companies, straight to your email. Email Address About Aldeyra TherapeuticsAldeyra Therapeutics (NASDAQ:ALDX) is a biotechnology company focused on developing therapies for immune-mediated diseases. The company’s approach centers on regulating the activity of reactive aldehyde species, which can contribute to inflammation and tissue damage. Aldeyra’s programs are primarily aimed at ophthalmic and other inflammatory conditions. The company’s lead investigational product is reproxalap, also known as ADX-102, a small-molecule reactive aldehyde species inhibitor being studied for eye diseases including dry eye disease and allergic conjunctivitis. Aldeyra has also evaluated reproxalap in other inflammatory disorders and maintains additional development programs designed to address diseases with significant unmet medical needs. Aldeyra was founded in 2008 and is headquartered in Lexington, Massachusetts. Its activities have largely centered on research, clinical development and regulatory evaluation in the United States, with its therapies remaining investigational rather than broadly commercialized. The company is led by Todd C. Brady, M.D., Ph.D., who serves as president and chief executive officer.View Aldeyra Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part Begins Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
